Advertisement
UK markets close in 6 hours 41 minutes
  • FTSE 100

    8,294.69
    +46.90 (+0.57%)
     
  • FTSE 250

    20,444.56
    +81.13 (+0.40%)
     
  • AIM

    767.62
    -0.41 (-0.05%)
     
  • GBP/EUR

    1.1847
    +0.0009 (+0.08%)
     
  • GBP/USD

    1.2667
    -0.0019 (-0.15%)
     
  • Bitcoin GBP

    48,589.93
    +659.29 (+1.38%)
     
  • CMC Crypto 200

    1,276.39
    -7.40 (-0.58%)
     
  • S&P 500

    5,469.30
    +21.43 (+0.39%)
     
  • DOW

    39,112.16
    -299.05 (-0.76%)
     
  • CRUDE OIL

    81.03
    +0.20 (+0.25%)
     
  • GOLD FUTURES

    2,328.00
    -2.80 (-0.12%)
     
  • NIKKEI 225

    39,667.07
    +493.92 (+1.26%)
     
  • HANG SENG

    18,089.93
    +17.03 (+0.09%)
     
  • DAX

    18,329.55
    +151.93 (+0.84%)
     
  • CAC 40

    7,689.60
    +27.30 (+0.36%)
     

Shire raises outlook after Q1 earnings beat

LONDON, May 1 (Reuters) - Shire (LSE: SHP.L - news) , a pharmaceutical group created by acquisition, soundly beat expectations with a 38 percent rise in first-quarter earnings, underlining its own appeal as a target in the latest wave of deal making in the sector.

Shire, which has franchises in drugs to treat hyperactivity and rare diseases, reported earnings per share-ADS of $2.36, its preferred measure, on revenue of $1.35 billion, boosted by strong sales across its portfolio.

The group raised its outlook for earnings growth this year to mid-to-high 20 percent growth from its previous prediction of similar growth to the 23 percent it recorded in 2013.

Allergan Inc (NYSE: AGN - news) , the botox maker, is preparing a takeover approach for Dublin-based Shire, Reuters reported on Tuesday.

ADVERTISEMENT

Shire, which has a market capitalization of $33 billion, has long outpaced its big pharma rivals growing revenues and profits. Its base in Dublin, which has a lower rate of corporation tax than many countries including the United States, adds to its appeal.

Analysts expected Shire to post revenue of $1.38 billion and non-GAAP earnings per ADS of $2.22, according to a company compiled poll of 19 brokers.

(Reporting by Paul Sandle; editing by Kate Holton)